

ASX WEEKLY EQUITY REPORT

CU6 Weekly Report

Clarity Pharmaceuticals Ltd

CU6 closed the latest completed week at 2.35 AUD. The 4-week return is 29.5% and the 12-week return is -19.0%. The trend backdrop is inactive, with activity pressure at -0.53.

Field	Value	Field	Value
Week ending	24 Jul 2026	Evidence rating	Caution
Evidence score	36	Currency	AUD
Exchange	ASX	Country	AU
Sector	Healthcare	Industry	Biotechnology
Market cap	928.7M	Report page	Available online

OPEN	HIGH	LOW	CLOSE	VOLUME	TREND
2.30 AUD	2.56 AUD	2.17 AUD	2.35 AUD	10.5M	30.8%
weekly open	weekly high	weekly low	weekly close	latest week	16 of 52 weeks active

Company brief

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops...

EXECUTIVE READ

What matters now

Top-level conclusion, primary support, and the main restraint in the current weekly setup.

Conclusion

The strongest supporting evidence is factors: O'Shaughnessy factor stack blends value, quality, momentum, and confidence. The main constraint is indicator analysis: Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12. The combined read is defensive, so risk control and evidence of stabilization matter more than headline upside.


Read	Pillar	Score	Detail
Primary support	Factors	62/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Main restraint	Indicator analysis	9/100	Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

WEEKLY TAPE

Price, Trend Line, and Fair Value

Price path, range position, trend distance, Fair Value gap, and return windows.

52-week price path



Black: weekly close. Green: Trend Line. Grey: Fair Value.

TREND DISTANCE -20.1% price vs Trend Line	FAIR GAP -32.2% price vs Fair Value	DRAWDOWN -60.0% from 52-week high	RANGE 13.5% 52-week range	VOLUME 0.9x vs 13-week average
---	---	---	---	--


Pillar	Score	Read	Detail
1W	1.3%	Positive	
4W	29.5%	Positive	
12W	-19.0%	Negative	
26W	-32.1%	Negative	
52W	-42.8%	Negative	

SETUP

Composite setup scorecard

Current setup pillars scored on the same 0-100 scale.

Composite radar



Pillar	Score	Read	Detail
Trend	17	Negative	
Momentum	100	Positive	
Activity Pressure	45	Neutral	
Relative Leadership	0	Negative	
Next-Week Expectancy	50	Neutral	
Volume	39	Neutral	
Smart Money	19	Negative	
Risk Control	0	Negative	

Current evidence clusters


Pillar	Score	Read	Detail
Price follow-through	1.3%	Positive	Latest completed week; four-week move 29.5%.
Indicator stack	17/45	Negative	Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop	Active	Positive	The trend backdrop defines the current weekly regime.
Patient Capital	Quiet	Neutral	Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment	49/100	Neutral	27 relevant articles in the latest sentiment read.

INDICATOR EVIDENCE

Activity pressure, trend confirmation, and next-week expectancy


The current 12-week confirmation window, activity-pressure read, and historical one-week setup read.

Activity pressure path



Latest 0.02 | 12-week average 0.03

Next-week expectancy path



Current Undecided 49.07% historical one-week setup read

Pillar	Score	Read	Detail
Trend active	0/12	Negative	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	0/12	Negative	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	0/12	Negative	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.02	Negative	Current proprietary activity-pressure read.
Buy signals	0	Neutral	Accumulation signal count in the latest 12 weeks.
Reversal markers	0	Positive	No reversal markers

Area	Latest read	Detail
Activity pressure	-0.53	Four-week pressure change 63.6%.
Relative leadership	-29.53	Four-week relative leadership change 37.1%.
Smart money activity	50	No recent accumulation markers. No reversal markers.

PARTICIPATION AND RISK

Volume, volatility, and return shape

Participation confirms attention; return shape frames the current risk profile.

Area	Latest	Baseline	Read
Volume	10.5M	13W 11.3M 52W 12.5M	0.9x vs 13-week average
Volatility	9.0%	52W 10.2%	25 upside weeks / 27 downside weeks
Average move	7.5%	-8.1%	Downside breadth 51.9%

Pillar	Score	Read	Detail
Participation	0.9x	Neutral	Latest volume versus the 13-week average.
Baseline	11.3M	Neutral	13-week average volume.
One-year base	12.5M	Neutral	52-week average volume.
Recent vol	9.0%	Neutral	13-week weekly-return volatility.
Base vol	10.2%	Neutral	52-week weekly-return volatility.
Up/down split	25/27	Negative	Count of positive and negative weeks in the 52-week window.
Average skew	7.5% / -8.1%	Neutral	Average positive week versus average negative week.

EXTERNAL CONFIRMATION

Options, sentiment, events, insiders, and research flow

Supporting evidence that can confirm, challenge, or qualify the weekly tape.

Pillar	Score	Read	Detail
Weekly tape	24/100	Negative	Trend, activity pressure, participation, and risk combine to a 24/100 tape read.
Indicator analysis	9/100	Negative	Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Factors	62/100	Neutral	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Patient Capital	Quiet	Neutral	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Sentiment	49/100	Neutral	Weighted news tone is neutral across 27 relevant articles.
Insiders	50/100	Neutral	No recent insider transaction evidence is stored.
Earnings	50/100	Neutral	No stored earnings event is currently attached to this ticker.

Evidence	Current read	Detail
Sentiment	49/100	27 relevant articles. Clarity Pharmaceuticals (ASX:CU6) Shares Advance While Investors Focus on Pipeline Progress

SECTOR CONTEXT

Sector and industry pulse

Group context helps separate stock-specific movement from broader rotation.

Group	Scope	Peers	4W rank	Trend breadth
Sector	AU Healthcare	100	8 of 100	22.0%
Industry	AU Biotechnology	47	9 of 47	19.1%

Sector leaders

Peer	Exchange	1W	4W	Trend
PTX	ASX	26.0%	50.8%	Off
PIQ	ASX	-11.4%	44.2%	Off
VIT	ASX	-3.2%	36.4%	Off
EZZ	ASX	5.1%	35.5%	Off
NEU	ASX	-3.0%	34.9%	Off

Industry leaders

Peer	Exchange	1W	4W	Trend
AGN	ASX	-3.1%	66.7%	Off
PTX	ASX	26.0%	50.8%	Off
PIQ	ASX	-11.4%	44.2%	Off
EZZ	ASX	5.1%	35.5%	Off
NEU	ASX	-3.0%	34.9%	Off

ACTIONABLE READ

Opportunities, risks, and watch points

Evidence clusters to monitor as the next weekly bar develops.

Opportunity signals

- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.

Risk signals

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.

Watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

EVIDENCE TRAIL

Recent completed weeks

Recent weekly bars behind the report.

Week	Close	Move	Trend	Activity	Volume
24 Jul	2.35 AUD	1.3%	Off	-0.53	10.5M
17 Jul	2.32 AUD	-3.7%	Off	-0.73	15.0M
10 Jul	2.41 AUD	9.0%	Off	-1.02	18.1M
03 Jul	2.21 AUD	21.8%	Off	-1.33	17.7M
26 Jun	1.81 AUD	-16.4%	Off	-1.47	24.3M
19 Jun	2.17 AUD	0.9%	Off	-1.59	1.8M
12 Jun	2.15 AUD	-4.4%	Off	-1.39	2.1M
05 Jun	2.25 AUD	-9.6%	Off	-1.11	11.5M
29 May	2.49 AUD	-9.1%	Off	-0.82	3.2M
22 May	2.74 AUD	-5.5%	Off	-0.51	11.4M

Report footer

Copyright 2026 Sharemaestro. All rights reserved.

[sharemaestro.com](#) | [Open this report online](#) | [Full disclaimer](#)

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.